Branded Generics Market Size & Share | Industry Analysis 2028

report image

Branded Generics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Therapeutic Application (Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics & Anti-Inflammatory, and Others), Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies, and Drug Stores), Drug Class (Alkylating Agents, Antimetabolites, Hormones, Antihypertensive, Lipid-Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptic, and Others), and Formulation Type (Oral, Parenteral, Topical, and Others)

Publication Month: Jun 2022 | Report Code: TIPRE00005554 | No. of Pages: 229 | Category: Pharmaceuticals | Status: Published

The branded generics market is expected to grow from US$ 235.86 billion in 2022 to US$ 414.99 billion by 2028; it is estimated to grow at a CAGR of 9.9% from 2022 to 2028.

Branded generics are generic drugs that have been given a proprietary market name. They may be marketed in a similar way as branded drugs. Branded generic drugs attach proprietary names to generic drug molecules. Some branded generics are specially made as novel dosage forms of off-patent drugs, filling in a dosage gap while offering consumers a name that is likely easier to remember than the true generic name. Branded generics are a small but profitable segment of the pharmaceutical market. Branded generics go through the same FDA approval process as other generics after branded drug patents expire.

According to a report released by VOXEU, with healthcare budgets worldwide under pressure, switching to branded generics seems a natural cost saver. Branded generics are cheaper alternatives to branded medicines, offering efficiency gains to any healthcare system. For instance, in 2016, US$ 253 billion was generated by generic medicines accounting for one-quarter of a trillion dollars. Additionally, US$ 1.6 trillion in healthcare savings in the same year accounted for in the US healthcare system evaluating a 10-year saving due to the availability of low-cost generics.

Strategic Insights

Report Coverage - Branded Generics Market
Report CoverageDetails
Market Size Value inUS$ 235.86 Billion in 2022
Market Size Value byUS$ 414.99 Billion by 2028
Growth rateCAGR of 9.9% from 2022 to 2028
Forecast Period2022-2028
Base Year2022
No. of Pages229
No. of Tables111
No. of Charts & Figures94
Historical data availableYes
Segments coveredTherapeutic Application, Distribution Channel, Drug Class, and Formulation Type
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available

The branded generics market is segmented based on therapeutic application, distribution channel, drug class, formulation type, and geography. By geography, the branded generics market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The branded generics market report offers insights and in-depth analysis of the market, emphasizing parameters such as market size, trends, technological advancements, and market dynamics, and the analysis of the competitive landscape of the globally leading market players.

The global branded generics market is majorly driven by the rising penetration of branded generics and increasing government initiatives for promoting branded generics. Additionally, encouraging utility of branded generics by healthcare providers and professionals is likely to emerge as a significant future trend in the market during the forecast period. However, poor clinical outcomes and adverse effects of generic medications in the global market are hampering the market growth.

Lucrative Regions in Branded Generics Market

Get more information on this report :

Market Insights
Rising Penetration of Branded Generics

According to a report released by VOXEU, with healthcare budgets worldwide under pressure, switching to branded generics seems a natural cost saver. Branded generics are cheaper alternatives to branded medicines, offering efficiency gains to any healthcare system. For instance, in 2016, US$ 253 billion was generated by generic medicines accounting for one-quarter of a healthcare industry.

Further, the Association for Accessible Medicines report states that nearly 3.9 billion generic prescriptions were dispensed in 2016. Therefore, branded generics present a viable opportunity for potential growth for big pharma players. According to the published report by HSRII, the US is the largest pharmaceutical market in the world (US$ 325 billion), accounting for one-third of the global pharmaceutical market, with generics accounting for 84% in terms of sales volume and 28% in terms of sales value. Furthermore, branded generics utilization has increased among the population due to savings provided by the healthcare system and the ability to invest in tomorrow's new medicines. For instance, nearly 3.9 billion prescriptions dispensed in the US are for generics. Moreover, on average, in 2016, the use of generic medicines saved each state US$ 4.9 billion compared to the price of relevant branded medicines. This further means that Medicaid savings averaged US$ 744 million, and state Medicaid savings averaged US$ 1.5 billion per state. Such factors accelerate the demand for branded generics, fueling the overall market growth during the forecast period.

Therapeutic Application-Based Insights

Based on therapeutic application, the global branded generics market has been segmented into oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, analgesics and anti-inflammatory, and others. In 2022, the others held the largest share of the market. However, the oncology segment is expected to grow at the fastest CAGR from 2022 to 2028.

Branded Generics Market, by Therapeutic Application – 2022 and 2028

Branded Generics Market, by Therapeutic Application – 2022 and 2028

Get more information on this report :

Distribution Channel-Based Insights

Based on distribution channel, the branded generics market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. The retail pharmacies segment is likely to hold the largest share of the market in 2022. Moreover, the online pharmacies segment is anticipated to register the highest CAGR in the market during the forecast period.

Drug Class-Based Insights

Based on drug class, the branded generics market is categorized into alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptic, and others. The others segment is likely to hold the largest share of the market in 2022. However, the hormones segment is anticipated to register the highest CAGR in the market during the forecast period.

Formulation Type-Based Insights

Based on formulation type, the branded generics market is segmented into oral, parenteral, topical, and others.  In 2022, the oral segment held the largest share of the market by formulation type. However, the parenteral segment is expected to grow at the fastest CAGR from 2022 to 2028.

Several companies adopt strategies such as product launches and approvals to expand their global footprints and product portfolios. Moreover, the branded generics market players focus on the partnership strategy to enlarge their clientele, allowing them to maintain their brand name globally. The market share is anticipated to flourish with market players' development of new innovative products. Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc., Bausch Health Companies Inc., Lupin, Sanofi, AstraZeneca Plc., Dr.Reddy’s Laboratories, Par Pharmaceuticals, Inc., Sandoz International GmbH, Aspen Holdings, and Hetero are among the leading companies operating in the global branded generics market.

Frequently Asked Questions

Branded generics are generic drugs that have been given a proprietary market name. They may be marketed similarly to how branded drugs are. Branded generic drugs attach proprietary names to generic drug molecules. Some branded generics are specially made as novel dosage forms of off-patent drugs, filling in a dosage gap while offering consumers a name that is likely easier to remember than the true generic name. Branded generics are a small, but profitable segment of the pharmaceutical market. Branded generics go through the same FDA approval process as other generics after branded drug patents expire.
The factors that are driving and restraining factors that will affect the branded generics market in the coming years. Growth of the global branded generics market is majorly driven by rising penetration of branded generics and increasing government initiatives for promoting branded generics. Additionally, encouraging utility of branded generics by healthcare providers and professionals is likely to emerge as a significant future trend in the market during the forecast period. However, poorer clinical outcomes and adverse effects of generic medications hamper the branded generics market growth.
The branded generics market majorly consists of the players such as Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc., Bausch Health Companies Inc., Lupin, Sanofi, AstraZeneca Plc., Dr.Reddy’s Laboratories, Par Pharmaceuticals, Inc., Sandoz International GmbH, Aspen Holdings, and Hetero amongst others.
The branded generics market, by therapeutical application, is bifurcated oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, analgesics and anti-inflammatory, and others. In 2022, the others segment held the largest share of the market, by therapeutic application. However, the oncology segment is expected to witness growth in its demand at a fastest CAGR during 2022 to 2028.

The List of Companies - Branded Generics Market

  1. MYLAN N.V.
  2. TEVA PHARMACEUTICAL INDUSTRIES LTD.
  3. GlaxoSmithKline plc
  4. Bausch Health (Valeant Pharmaceuticals)
  5. Sandoz International Gmbh
  6. Aspen Holdings
  7. Par Pharmaceuticals
  8. Lupin
  9. Sanofi
  10. AstraZeneca
  11. Dr. Reddy's Laboratories Inc.
  12. Hetero
  • The key findings and recommendations highlight crucial progressive industry trends in the global Branded Generics market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • A brief idea about the current competition in the Branded Generics Market.
  • Provide strong and enough study of Branded Generics market that help in understanding the market.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the global Branded Generics market.
  • Highlights key business priorities and focus in order to assist companies to realign their business strategies.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TIPRE00005554
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market


Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount